Pertussis is an acute respiratory infection caused by Bordetella pertussis. Rates of recent B. pertussis infection between 8%--26% have been reported among adults with cough illness of at least 5 days duration who sought medical care. The CDC recommends vaccinating patients aged 15 to 64 years old, once in 10 years. Although acellular vaccines such as BOOSTRIX have been evaluated in healthy population, the safety and efficacy of this vaccine in patients suffering from rheumatic diseases have not been established. Study population : 50 Rheumatoid Arthritis (RA) patients and 5 healthy controls Evaluation : the evaluation will be performed on week 0 and 4-6 weeks later. In terms of safety, the patients will be evaluated according to the Disease Activity Index (DAS). Blood will be drawn at each visit at tested for humoral response to tetanus and pertussis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
100
a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
Department of Rheumatology, Tel Aviv Medical Center
Tel Aviv, Israel
Immunogenicity of Tdap in patients suffering from rheumatoid arthritis
Geometric mean titers and individual responses to components of pertussis, tetanus and diphtheria
Time frame: 4-6 weeks after vaccination
Safety of Tdap vaccine in RA patients
Safety will be evaluated using the disease activity score (DAS) at baseline and 4-6 weeks later
Time frame: 4-6 weeks after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.